Mechanisms Of Interleukin -17 In The Pathogenesis Of Neutrophilic Asthma

Authors:
  • CUCopperbelt University
    Copperbelt University
  • NSNightingale Syabbalo
    Nightingale Syabbalo

Abstract
Asthma is a complex chronic airway disease with several distinct phenotypes characterized by different immunopathological pathways, clinical presentation, physiology, comorbidities, biomarker of allergic inflammation, and response to treatment. Approximately 10% of patients with asthma have severe refractory disease, which is difficult to control on high doses of inhaled corticosteroids, and long-acting ?2-agonists. About 50% of these individuals suffer from neutrophilic asthma. Neutrophilic asthma is a phenotype of asthma that is severe and persistent, with frequent exacerbations, and is characterized by fixed airway obstruction. It is associated with comorbidities such as respiratory infections, obesity, gastroesophageal reflux disease, and obstructive sleep apnea. Immunopathologically, it is characterized by the presence of high levels of neutrophils in the lungs and airways. Interleukin-17 secreted by Th17 cells, plays a key role in the pathogenesis of neutrophilic asthma by expressing the secretion of chemoattractant cytokines, and chemokines for the recruitment and activation of neutrophils. Activated neutrophils produce oxidative bursts, releasing multiple proteinases, cytokines, chemokines, and reactive oxygen species which cause airway epithelial cell injury, inflammation, and hyperresponsiveness. During respiratory infections, and allergic inflammation, neutrophils can release neutrophil extracellular traps and cytoplasts, which can damage epithelial cells leading to further airway inflammation.